vs
Qorvo, Inc.（QRVO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Qorvo, Inc.的季度营收约是Revvity的1.3倍（$993.0M vs $772.1M），Qorvo, Inc.净利率更高（16.5% vs 12.7%，领先3.8%），Qorvo, Inc.同比增速更快（8.4% vs 5.9%），Qorvo, Inc.自由现金流更多（$236.9M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 2.7%）
Qorvo是一家美国跨国企业，专注于无线、有线及电源市场相关产品的研发与供应。该公司由TriQuint半导体与RF Micro Devices合并而来，合并计划于2014年公布，2015年1月1日正式完成，在纳斯达克挂牌上市，股票代码QRVO，原实行双总部制，2016年中起将北卡罗来纳州基地作为总部所在地。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
QRVO vs RVTY — 直观对比
营收规模更大
QRVO
是对方的1.3倍
$772.1M
营收增速更快
QRVO
高出2.5%
5.9%
净利率更高
QRVO
高出3.8%
12.7%
自由现金流更多
QRVO
多$75.1M
$161.8M
两年增速更快
RVTY
近两年复合增速
2.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $993.0M | $772.1M |
| 净利润 | $164.1M | $98.4M |
| 毛利率 | 46.7% | — |
| 营业利润率 | 19.4% | 14.5% |
| 净利率 | 16.5% | 12.7% |
| 营收同比 | 8.4% | 5.9% |
| 净利润同比 | 297.5% | 3.9% |
| 每股收益（稀释后） | $1.75 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QRVORVTY
| Q4 25 | $993.0M | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $818.8M | $720.3M | ||
| Q1 25 | $869.5M | $664.8M | ||
| Q4 24 | $916.3M | $729.4M | ||
| Q3 24 | $1.0B | $684.0M | ||
| Q2 24 | $886.7M | $691.7M | ||
| Q1 24 | $941.0M | $649.9M |
净利润QRVORVTY
| Q4 25 | $164.1M | $98.4M | ||
| Q3 25 | $119.6M | $46.7M | ||
| Q2 25 | $25.6M | $53.9M | ||
| Q1 25 | $31.4M | $42.2M | ||
| Q4 24 | $41.3M | $94.6M | ||
| Q3 24 | $-17.4M | $94.4M | ||
| Q2 24 | $414.0K | $55.4M | ||
| Q1 24 | $2.7M | $26.0M |
毛利率QRVORVTY
| Q4 25 | 46.7% | — | ||
| Q3 25 | 47.0% | 53.6% | ||
| Q2 25 | 40.5% | 54.5% | ||
| Q1 25 | 42.2% | 56.5% | ||
| Q4 24 | 42.7% | — | ||
| Q3 24 | 42.6% | 56.3% | ||
| Q2 24 | 37.5% | 55.7% | ||
| Q1 24 | 40.6% | 54.6% |
营业利润率QRVORVTY
| Q4 25 | 19.4% | 14.5% | ||
| Q3 25 | 14.9% | 11.7% | ||
| Q2 25 | 3.7% | 12.6% | ||
| Q1 25 | 3.2% | 10.9% | ||
| Q4 24 | 5.8% | 16.3% | ||
| Q3 24 | 0.9% | 14.3% | ||
| Q2 24 | 0.5% | 12.4% | ||
| Q1 24 | 3.2% | 6.8% |
净利率QRVORVTY
| Q4 25 | 16.5% | 12.7% | ||
| Q3 25 | 11.3% | 6.7% | ||
| Q2 25 | 3.1% | 7.5% | ||
| Q1 25 | 3.6% | 6.4% | ||
| Q4 24 | 4.5% | 13.0% | ||
| Q3 24 | -1.7% | 13.8% | ||
| Q2 24 | 0.0% | 8.0% | ||
| Q1 24 | 0.3% | 4.0% |
每股收益（稀释后）QRVORVTY
| Q4 25 | $1.75 | $0.86 | ||
| Q3 25 | $1.28 | $0.40 | ||
| Q2 25 | $0.27 | $0.46 | ||
| Q1 25 | $0.33 | $0.35 | ||
| Q4 24 | $0.43 | $0.77 | ||
| Q3 24 | $-0.18 | $0.77 | ||
| Q2 24 | $0.00 | $0.45 | ||
| Q1 24 | $0.04 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $919.9M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $3.7B | $7.3B |
| 总资产 | $6.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.42× | — |
8季度趋势，按日历期对齐
现金及短期投资QRVORVTY
| Q4 25 | $1.3B | $919.9M | ||
| Q3 25 | $1.1B | $931.4M | ||
| Q2 25 | $1.2B | $991.8M | ||
| Q1 25 | $1.0B | $1.1B | ||
| Q4 24 | $769.4M | $1.2B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.1B | $2.0B | ||
| Q1 24 | $1.0B | $1.7B |
总债务QRVORVTY
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
股东权益QRVORVTY
| Q4 25 | $3.7B | $7.3B | ||
| Q3 25 | $3.5B | $7.4B | ||
| Q2 25 | $3.4B | $7.6B | ||
| Q1 25 | $3.4B | $7.6B | ||
| Q4 24 | $3.4B | $7.7B | ||
| Q3 24 | $3.4B | $7.9B | ||
| Q2 24 | $3.5B | $7.9B | ||
| Q1 24 | $3.6B | $7.8B |
总资产QRVORVTY
| Q4 25 | $6.2B | $12.2B | ||
| Q3 25 | $6.1B | $12.1B | ||
| Q2 25 | $6.0B | $12.4B | ||
| Q1 25 | $5.9B | $12.4B | ||
| Q4 24 | $6.0B | $12.4B | ||
| Q3 24 | $6.5B | $12.8B | ||
| Q2 24 | $6.4B | $13.4B | ||
| Q1 24 | $6.6B | $13.4B |
负债/权益比QRVORVTY
| Q4 25 | 0.42× | — | ||
| Q3 25 | 0.44× | — | ||
| Q2 25 | 0.45× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — | ||
| Q1 24 | 0.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $265.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $236.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 23.9% | 21.0% |
| 资本支出强度资本支出/营收 | 2.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.62× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $595.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流QRVORVTY
| Q4 25 | $265.4M | $182.0M | ||
| Q3 25 | $84.0M | $138.5M | ||
| Q2 25 | $182.9M | $134.3M | ||
| Q1 25 | $199.2M | $128.2M | ||
| Q4 24 | $214.1M | $174.2M | ||
| Q3 24 | $127.8M | $147.9M | ||
| Q2 24 | $81.1M | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流QRVORVTY
| Q4 25 | $236.9M | $161.8M | ||
| Q3 25 | $42.2M | $120.0M | ||
| Q2 25 | $145.4M | $115.5M | ||
| Q1 25 | $170.7M | $112.2M | ||
| Q4 24 | $176.2M | $149.8M | ||
| Q3 24 | $94.8M | $125.6M | ||
| Q2 24 | $42.9M | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率QRVORVTY
| Q4 25 | 23.9% | 21.0% | ||
| Q3 25 | 4.0% | 17.2% | ||
| Q2 25 | 17.8% | 16.0% | ||
| Q1 25 | 19.6% | 16.9% | ||
| Q4 24 | 19.2% | 20.5% | ||
| Q3 24 | 9.1% | 18.4% | ||
| Q2 24 | 4.8% | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度QRVORVTY
| Q4 25 | 2.9% | 2.6% | ||
| Q3 25 | 3.9% | 2.6% | ||
| Q2 25 | 4.6% | 2.6% | ||
| Q1 25 | 3.3% | 2.4% | ||
| Q4 24 | 4.1% | 3.4% | ||
| Q3 24 | 3.2% | 3.3% | ||
| Q2 24 | 4.3% | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率QRVORVTY
| Q4 25 | 1.62× | 1.85× | ||
| Q3 25 | 0.70× | 2.97× | ||
| Q2 25 | 7.15× | 2.49× | ||
| Q1 25 | 6.35× | 3.03× | ||
| Q4 24 | 5.19× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 195.86× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QRVO
| ACG | $690.8M | 70% |
| HPA | $190.9M | 19% |
| CSG | $111.3M | 11% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
